U.S. biotech sector rallies broadly, Genmab extends intraday gains to over 25% to hit all-time high

Odaily reports: According to MSX.COM data, biotech company Genmab extended its intraday gains to over 25%, with its share price hitting an all-time high. The company announced the latest data from its Phase III LiGeR-HN1 study of Petosemtamab, showing that the combination therapy can reduce the risk of death by 50% in patients with head and neck squamous cell carcinoma.

Among U.S. biotech stocks, Twist Bioscience rose over 9%, Recursion Pharmaceuticals gained more than 8%, and Moderna climbed over 4%.